Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.

Cancer gene therapy - 1 Aug 2006

Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, Yura Y

Abstract excerpt

Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 for human oral squamous cell carcinoma (SCC) cells. Hexamethylene bisacetamide increased the viral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Genes, Immediate-Early

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Mice, Nude

Share to Mouth Neoplasms

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 16645620
DOI: 10.1038/sj.cgt.7700957

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.PMID 16645620Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

[Progess on research of herpes simplex virus type 1 mutants for cancer therapy].Semantic proximity Read ↗

Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Active immunotherapy: oncolytic virus therapy using HSV-1.Semantic proximity Read ↗

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved TolerabilitySemantic proximity Read ↗

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasSemantic proximity Read ↗

Medical application of herpes simplex virus.Semantic proximity Read ↗

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.